is the goal. Similarly, their migration competence in vivo is relatively restricted, compared to their glial progenitor progeny, which are considerably more effective at long-distance migration and dispersal. As a result, NSCs may not be as appropriate vectors for the treatment of glial and myelin disorders as more restricted, and hence functionally dedicated, glial progenitor cells. Yet for both MSCs and NSCs, the tendency of commercial entities in particular to pursue these phenotypes, despite their manifest limitations as therapeutic vectors, may stem not only from purely commercial considerations as operative intellectual property and freedom to operate, but also from the clinical scale homogeneity and expandability that may be achieved using these phenotypes. Such scalability is a necessary condition for the broad clinical adoption of any cell therapeutic, and yet this prerequisite has thus far proven elusive for both glial and lineage-restricted neuronal progenitor cells.
